Location of Repository

Playing both sides: nucleophosmin between tumor suppression and oncogenesis

By Pier Paolo Di Fiore

Abstract

Nucleophosmin (NPM) is frequently mutated in acute myeloid leukemias and is thought to act as both a proto-oncogene and a tumor suppressor. Although genetic and molecular evidence has shed light on the mechanisms of NPM-mediated tumor suppression, the potential role of NPM mutants as oncogenes remains ill defined. Now, new data provide a straightforward mechanism for this latter function, as NPM is shown to regulate the stability and the function of MYC. Remarkably, the same leitmotif of “placing a critical cell regulator in the wrong place at the wrong time” appears to underscore all the cancer-promoting activities of mutated NPM

Topics: Reviews
Publisher: The Rockefeller University Press
OAI identifier: oai:pubmedcentral.nih.gov:2447893
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
    2. (2006). Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res.
    3. (2008). Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 .
    4. (2005). Nucleophosmin is required for DNA integrity and p19Arf protein stability.
    5. (2005). Role of nucleophosmin in embryonic development and tumorigenesis.
    6. (2007). Ubiquitinindependent degradation of cell-cycle inhibitors by the REGgamma proteasome.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.